SLC5A2 and type 2 diabetes mellitus: Empagliflozin is a sodium-glucose transport protein 2 (SGLT2) inhibitor used for type 2 diabetes, that was shown to reduce the content of sphingomyelin and ceramide in the heart of type 2 diabetic rats (222).